Addition of aprepitant may improve vomiting control in patients receiving oxaliplatin
the ONA take:
According to results presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have found that a three-drug combination antiemetic therapy including aprepitant or fosaprepitant significantly improved the prevention rate of nausea and vomiting in patients receiving oxaliplatin chemotherapy.
For the multicenter, open-label, phase III SENRI Trial, researchers enrolled 413 Japanese patients with colorectal cancer who were receiving oxaliplatin-based chemotherapy. Patients were randomly assigned 1:1 to receive a 5-HT3 receptor antagonist plus dexamethasone with or without aprepitant or fosaprepitant during the first course of chemotherapy. All patients received aprepitant or fosaprepitant in subsequent courses.
Results showed that significantly more patients who received an NK1 antagonist achieved no vomiting overall and no vomiting in the delayed phase than those in the control arm. Researchers also found that women had higher rates of no nausea and complete protection in the aprepitant arm than the control arm.
The standard protocol for prevention of chemotherapy-induced nausea and vomiting in patients receiving oxaliplatin-based chemotherapy is a 5-HT3 receptor antagonist plus dexamethasone.
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|